According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Medicines, including insulin, to be available in 40 lower-income countries
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Subscribe To Our Newsletter & Stay Updated
